Company Description
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.
The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases.
The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform.
It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis.
The company was founded in 2014 and is based in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 908 |
| CEO | Matthew Gline |
Contact Details
Address: 50 Broadway, 7th Floor London, SW1H 0DB United Kingdom | |
| Phone | 44 20 7400 3347 |
| Website | roivant.com |
Stock Details
| Ticker Symbol | ROIV |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001635088 |
| CUSIP Number | G76279101 |
| ISIN Number | BMG762791017 |
| Employer ID | 98-1173944 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Gline | Chief Executive Officer |
| Richard Pulik | Chief Financial Officer |
| Eric Venker | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | 144 | Filing |
| Dec 20, 2024 | 144 | Filing |
| Dec 18, 2024 | 144 | Filing |
| Dec 3, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |